Since their development as synthetic antimalarial drugs during the second world war the 4-aminoquinolines have enjoyed a role of expanding importance throughout the world and are now regarded as the drugs of choice, both for suppression and for therapy, in malaria (Coatney, 1963) . Though resistance of human plasmodia to pyrimethamine and proguanil has long been known, the recognition of 4-aminoquinoline-resistant strains of Plasmodium falciparum is of relatively recent occurrence. Since 1961, strains showing abnormal response to chloroquine have been reported from Colombia (Young and Moore, 1961 ; Young, 1962; Moore and Lanier, 1963; Powell et al., 1963) , and Brazil (Rodrigues Da Silva et al., 1961; Box et al., 1963) in South America, and from Thailand , Vietnam (Powell et al., 1963) , Cambodia (Contacos et al., 1963) , and Malaya Sandosham et al., 1963) MIZlo developed malaria, confirmed by a thick blood smear, after having regularly received the drug in daily doses for periods ranging from 15 to 55 days.
Explanations of apparent "breakthroughs " must take into account a number of variables: irregularity of drug-taking underdosage, intercurrent gastro-intestinal illness interfering with absorption of the drug, unusually great exposure to infection, fatigue and generally lowered host resistance from whatever cause, including climatic and altitude changes, the presence of resistant strains of malaria parasites, or other unknown factors (Bruce-Chwatt and Horn, 1958) .
As it is notoriously difficult to be certain of the good faith of out-patients about taking suppressive medication, many of the so-called " breakthroughs " result probably from failure to take the drug regularly. However, it was possible to eliminate this variable as all the patients were in hospital and were under the direct supervision of the medical and nursing staff of the paediatric service. The drugs were personally administered by responsible nursing personnel, and in cases of vomiting or spitting the drug was administered by stomach-tube.
Malabsorption of the drug from the gastro-intestinal tract may accompany diarrhoeal and nutritional diseases. Children with diarrhoea or evidence of malabsorption were therefore excluded.
The positive urine tests confirm the absorption of the drug in at least two of the nine patients.
It is possible that these attacks of malaria may represent the relapse of an existing infection rather than a new infection or reinfection. However, the dosages of chloroquine given were large and were continued for a long period, presumably producing blood levels that should have eradicated any pre-existing infection. Cases 2 and 7 because of their amoebiasis received more than therapeutic doses for 17 and 6 days respectively; Case 9 because of the malaria infection on admission received very high doses for 37 days ; and Cases 3 and 8 received high dosages by error. With dosage levels of this magnitude the question of reinfection versus relapse becomes academic: the chloroquine failed to suppress the attack of malaria.
Another possibility that must be excluded is the lowered resistance of children ill enough to require admission to hospital: could this have permitted these "breakthroughs" ? Here it is significant to note that all the children responded satisfactorily to other antimalarial drugs administered in therapeutic dosages ; this suggests that general debilitation and lowered host resistance did not play an important part.
Part II-Failure of Treatment
The drug chiefly used in the Ouagadougou Hospital for the treatment of malaria is Nivaquine (chloroquine sulphate), and dosages are based on those recommended by Schneider (1960). According to this schedule children up to 1 year of age should receive 100 mg. of the drug daily for two days and 50 mg. daily for the next three days; those aged 1-3 years should receive 150 mg. daily for two days and 100 mg. daily Malaria-Lasch and N'Guyen BRITISH The curative action of chloroquine is usually thought to be very rapid; in the 46 cases summarized by Jeffery et al. (1956) 61% were clear of parasites in two days, and only two showed a parasitaemia five days after treatment. Symptoms abated even more rapidly, and in no case did a fever over 380 C. persist after two days of treatment. Young and Eyles (1963) give criteria for detecting resistance of P. falciparum to chloroquine. In their opinion prime evidence of resistance to the drug is the persistence of fever 72 hours after the beginning of treatment, a higher parasitaemia after 48 hours than before treatment, and the occurrence of parasites in the blood-stream after six days. If we apply these results and criteria to Case 14 we see that resistance of the infection to the drug was very probable, because not only had the fever not abated after seven days of treatment and after double the usual dose of chloroquine, but the parasitaemia was higher than before.
The second problem is that of relapse. If we again cite Jeffery et al. (1956) we see that among his cases only one out of 46 who received the normal dosage relapsed, and only three relapsed of the 18 patients who had received a single dosage of 400 mg. intramuscularly. Covell et al. (1955) state categorically that chloroquine produces radical cure of P. falciparum. Young and Eyles (1963) maintain that reappearance of parasites in the blood-stream within three weeks is indicative of resistance. In comparison with these findings our Cases 10 and 11 relapsed within a week while still under relatively high preventive dosages ; in Case 12 there was a relapse while still receiving therapeutic dosages ; in Case 13 a relapse occurred on the nineteenth day after the attack while still under a high preventive regime ; and in Case 15 there was a relapse 24 hours after completion of intramuscular therapy. All of these patients relapsed after having received much larger dosages than those usually prescribed for their respective age groups ; the relapse occurred very shortly after treatment, and while preventive treatment was still being given.
Another problem is posed by Case 11. It has always been thought that if there was a breakthrough of malaria under prevention it was usually mild and could easily be brought under control. But in this case the relapse, which occurred not only under preventive treatment but a short time after the end of treatment, took the form of a pernicious cerebral attack which ended with the patient's death.
Conclusions
The 15 cases reported demonstrate that in this part of West Africa chloroquine, even when given in high dosages, does not always prevent attacks of malaria (nine cases), does not cure all cases, and does not prevent relapses.
As already stated, the possibility that a strain of P. falciparum resistant to chloroquine exists in Upper Volta has been suspected, but to the best of our knowledge no systematic studies have vet been carried out.
The cases reported tend to strengthen these suspicions. Clinical considerations, however, did not always allow us to follow a rigorous experimental routine, and because of lack of certain laboratory facilities we do not regard our findings as an absolute proof of resistance. Therefore this report is presented as a preliminary one. Still, it does appear that the behaviour of the parasites towards the drug was abnormal in all the cases recorded, since they showed a sensitivity towards it which was lower than usual. In our opinion the most plausible explanation would be that there exists in these cases a resistance towards chloroquine.
On the other hand, this presumed resistance appears not to be universal; there are many cases which react favourably to chloroquine in the area under study. Even among the cases reported five out of six showed some response to chloroquine in that the infections could be controlled while not cured.
Resistance of this strain to other antimalarial drugs could not be demonstrated. All patients reacted promptly when given quinine, amodiaquine, or a combination of both.
As we have said, this paper, containing clinical but not experimental data, is to be regarded as a preliminary report. Epidemiological considerations are beyond its scope. Plans, however, are being drawn up for more detailed studies in cooperation with laboratories specializing in these problems.
Summary
In 15 African children from Upper Volta, West Africa, an abnormal response of P. falciparum to chloroquine has been observed. All cases were hospitalized and kept under close medical supervision.
Nine of the cases demonstrated breakthroughs while under massive suppressive doses. In six cases the P. falciparum infection could not be controlled by large dosages of chloroquine. In one of these cases there was no reaction whatsoever to treatment, and the other five relapsed soon after the infection had apparently been controlled.
There is reason to suspect, therefore, that one or several chloroquine-resistant strains of P. falciparum exist in this part of West Africa.
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